½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)
Neurological Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 to 2034
»óǰÄÚµå : 1639201
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 130 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ¼¼°è ½ÃÀåÀº 2024³â 95¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, 2025³âºÎÅÍ 2034³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 10.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾ËÃ÷ÇÏÀ̸Ӻ´°ú ÆÄŲ½¼º´°ú °°Àº ½Å°æÅðÇ༺ ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Å°æÁúȯ Áõ°¡´Â ÁÖ·Î Àα¸ÀÇ °í·ÉÈ­¿¡ ±âÀÎÇϰí ÀÖÀ¸¸ç, ¾ËÃ÷ÇÏÀ̸Ӻ´Àº ³ëÀÎµé »çÀÌ¿¡¼­ Á¡Á¡ ´õ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Áúº´ÀÇ ±ÞÁõÀº ¸ÂÃãÇü Ä¡·á°¡ ȯÀÚÀÇ ¿¹ÈÄ °³¼±À¸·Î À̾îÁö±â ¶§¹®¿¡ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ºÎÃß±â°í ÀÖ½À´Ï´Ù. À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, À̹Ì¡ ±â¼úÀÇ ¹ßÀüµµ ½Å°æÁúȯÀÇ Á¶±â ¹ß°ß ¹× Áø´Ü¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ³ú¿Í Ç÷¾×¿¡¼­ ƯÁ¤ ´Ü¹éÁú, À¯ÀüÀÚ ¹× ´ë»ç»ê¹°À» È®ÀÎÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿´Â Áø´Ü Á¤È®µµ¸¦ ÇöÀúÇÏ°Ô Çâ»ó½ÃÄÑ ÀÇ·á Àü¹®°¡°¡ Àû½Ã¿¡ È¿°úÀûÀÎ Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

½Å°æÇÐÀû ¹ÙÀÌ¿À¸¶Ä¿´Â ´Ù¾çÇÑ ½Å°æÁúȯÀÇ Á¸Àç¿Í ÁøÇàÀ» Æò°¡Çϱâ À§ÇÑ Áß¿äÇÑ ÁöÇ¥°¡ µË´Ï´Ù. ÀÌ ¹ÙÀÌ¿À ¸¶Ä¿´Â ¾ËÃ÷ÇÏÀÌ¸Ó º´, ÆÄŲ½¼ º´, ´Ù¹ß¼º °æÈ­Áõ, ÀÚÆóÁõ ½ºÆåÆ®·³ Àå¾Ö¿Í °°Àº Áúº´°ú °ü·ÃµÈ ºÐÀÚ, À¯ÀüÀÚ ¹× ±âŸ ¹°ÁúÀÔ´Ï´Ù. ½ÃÀåÀº Á¦Ç° À¯Çüº°·Î ´Ü¹éÁúüÇÐ, À¯Àüü, ¸ÞŸº¼·Ò, À̹Ì¡ ¹× ±âŸ ¹ÙÀÌ¿À¸¶Ä¿·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áß ´Ü¹éÁúüÇÐ ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ß´Â ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ Áú·® ºÐ¼®(LC-MS/MS)°ú ¸ÖƼÇ÷º½º ºÐ¼® µî ±â¼úÀÇ ¹ßÀüÀ¸·Î 2024³â¿¡´Â 31¾ï ´Þ·¯¸¦ Â÷ÁöÇØ ½ÃÀåÀ» °ßÀÎÇß½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ¿¬µµ 2024
¿¹Ãø¿¬µµ 2025-2034
½ÃÀÛ±Ý¾× 95¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 266¾ï ´Þ·¯
CAGR 10.9%

ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ´Ü¹éÁúüÇÐ °Ë»çÀÇ °¨µµ¿Í ½Å·Ú¼ºÀ» Çâ»ó½ÃÄÑ ½Å°æ ÁúȯÀÇ Á¶±â ¹ß°ß°ú ´õ ³ªÀº °ü¸®¸¦ °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. °Ô´Ù°¡ Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÓ»ó ÇöÀå°ú ÀǾàǰ °³¹ß ¸ðµÎ¿¡¼­ ´Ü¹éÁúüÇÐ ¹ÙÀÌ¿À¸¶Ä¿ ¼ö¿ä°¡ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áúº´ À¯Çüº°·Î ¾ËÃ÷ÇÏÀ̸Ӻ´Àº 2024³â¿¡ 45.5%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç Á¶±â Áø´Ü ¼Ö·ç¼ÇÀÇ ±ä±Þ ¿ä±¸¸¦ ¹Ý¿µÇÕ´Ï´Ù. Ç÷¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿´Â ±âÁ¸ÀÇ ³úô¼ö¾× °Ë»ç¸¦ ´ëüÇϴ ħ½À¼ºÀÌ ³·°í ºñ¿ë È¿À²ÀûÀÎ ¿É¼ÇÀ¸·Î µîÀåÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

2024³â ÃÖÁ¾ ¿ëµµº° ½ÃÀå ±Ô¸ð¿¡¼­´Â º´¿ø ¹× Áø·á¼Ò ½ÃÀåÀÌ ¾ÐµµÀûÀ̸ç, 2034³â¿¡´Â 110¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¼³¿¡¼­´Â ºñħ½ÀÀû ¹ÙÀÌ¿À¸¶Ä¿ Áø´ÜÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, °³ÀÎÈ­ Äɾ ÅëÇØ ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ Áö¿ø, ¿¬±¸ ÀÚ±Ý, ¹Î°£ ´Üü¿ÍÀÇ Á¦ÈÞµµ ÀÏ»ó ÀÓ»ó¿¡ ´ëÇÑ ¹ÙÀÌ¿À ¸¶Ä¿ÀÇ ÅëÇÕÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì¿¡¼­´Â ¹Ì±¹ÀÌ 2024³â ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð´Â 37¾ï ´Þ·¯¿´½À´Ï´Ù. ÀÌ Áö¿ªÀº ±â¼úÀÇ ¹ßÀü, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, °³ÀÎÀÇ À¯ÀüÀû ÇÁ·ÎÆÄÀÏ ¹× Áúº´ ÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â °³ÀÎÈ­ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : Á¦Ç° À¯Çüº°, 2021³â-2034³â

Á¦6Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : Áúȯ À¯Çüº°, 2021³â-2034³â

Á¦7Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021³â-2034³â

Á¦8Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : Áö¿ªº°, 2021³â-2034³â

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Neurological Biomarkers Market was valued at USD 9.5 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 10.9% between 2025 and 2034. The rising prevalence of neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, is a key factor driving market growth. This increase in neurological conditions is primarily attributed to the aging population, with Alzheimer's disease becoming increasingly common among older adults.

The surge in these disorders has fueled demand for personalized medicine, as tailored treatments can lead to better outcomes for patients. Advancements in genomics, proteomics, and imaging technologies are also playing a pivotal role in the early detection and diagnosis of neurological diseases. Biomarkers that identify specific proteins, genes, or metabolites in the brain or blood have significantly enhanced diagnostic accuracy, enabling healthcare professionals to provide timely and effective treatment.

Neurological biomarkers serve as critical indicators for assessing the presence and progression of various neurological diseases. These biomarkers can be molecules, genes, or other substances linked to conditions such as Alzheimer's, Parkinson's, multiple sclerosis, and autism spectrum disorders. The market is segmented by product type into proteomic, genomic, metabolomic, imaging, and other biomarkers. Among these, the proteomic biomarker segment led the market in 2024, accounting for USD 3.1 billion, driven by advancements in technologies like liquid chromatography-mass spectrometry (LC-MS/MS) and multiplex assays.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$9.5 Billion
Forecast Value$26.6 Billion
CAGR10.9%

These innovations have improved the sensitivity and reliability of proteomic tests, allowing for earlier detection and better management of neurological conditions. Additionally, the growing focus on precision medicine is expected to boost demand for proteomic biomarkers in both clinical settings and drug development.

By disease type, Alzheimer's disease held the largest market share of 45.5% in 2024, reflecting the urgent need for early diagnostic solutions. Blood-based biomarkers have emerged as a less invasive and more cost-effective alternative to traditional cerebrospinal fluid tests, further driving market growth.

The hospitals and clinics segment dominated the market by end use in 2024 and is projected to reach USD 11 billion by 2034. These facilities are increasingly adopting non-invasive biomarker diagnostics, improving patient outcomes through personalized care. Government support, funding for research, and collaborations with private organizations are also accelerating the integration of biomarkers into routine clinical practice.

In North America, the U.S. held a significant share of the neurological biomarkers market in 2024, valued at USD 3.7 billion. The region benefits from technological advancements, increased focus on precision medicine, and a rising demand for personalized therapies tailored to individual genetic and disease profiles.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â